Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease associated with substantial morbidity as well as increased mortality 1 . A considerable body of evidence implicates B cells in the pathogenesis of SLE, and successful use of the B-cell-depleting agent rituximab in patients with SLE has been reported in numerous open-label studies (reviewed elsewhere) 2 . However, two randomized controlled trials of rituximab therapy in patients with SLE (EXPLORER 3,4 and LUNAR
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. A considerable body of evidence implicates B cells in the pathogenesis of SLE, and successful use of the B-cell-depleting agent rituximab in patients with SLE has been reported in numerous open-label studies (reviewed elsewhere) 2 . However, two randomized controlled trials of rituximab therapy in patients with SLE (EXPLORER 3, 4 and LUNAR 5 ) did not meet their primary end points. Some researchers have cogently argued that various aspects of trial design could account for these failures 2 , and accordingly further trials of rituximab in patients with SLE are now planned or underway. However, in this Opinion article we propose a different explanation for the failure of these trials -specifically that rituximab therapy triggers a surge in BAFF (B-cell-activating factor, also known as TNF ligand superfamily member 13B or BLyS) levels, which exacerbates disease in some patients with SLE.
repopulating B-cell pool, compared with patients who remained in remission and those who relapse without increased levels of anti-dsDNA antibodies 6 . Elevated plasmablast numbers following rituximab treatment have been associated with a shorter interval to subsequent relapse 7 . An increased frequency of peripheral blood plasmablasts is generally associated with active disease in patients with SLE, and this B-cell subset is considered to have a role in driving the disease 8 . The number of CD27 high plasmablasts in patients with SLE is closely correlated with SLE disease activity indices, and with anti-dsDNA antibody levels 9 . Following B-cell depletion therapy, having a high percentage of plasmablasts (presumably producing autoantibodies) within the residual B-cell pool could trigger an SLE flare despite low overall B-cell numbers. Patients who have a high proportion of plasmablasts also often have few transitional B cells, a compartment rich in regulatory B cells. Deficiency in this suppressive population could also contribute to an earlier relapse of disease 10 .
Human peripheral blood plasmablasts promote the differentiation of T follicular helper (T FH ) cells, partly via IL-6 (REFS 11, 12) . T FH cells can in turn stimulate plasmablast formation, thereby creating a positive feedback loop and perpetuating disease (FIG. 1) . In support of these observations in humans, differentiation of T FH cells in mouse models of infection is also dependent upon B-cell production of IL-6 (REF. 13 ). The frequency of T FH cells correlates with plasmablast numbers, anti-dsDNA antibody levels and disease activity (particularly the severity of glomerulonephritis) in SLE [14] [15] [16] . Moreover, circulating T FH cells in patients with SLE are capable of driving the differentiation of B cells into plasmablasts in vitro 17 . Ectopic clusters of T FH cells and B cells are present in the inflamed kidneys of patients with SLE and, together with conventional germinal centre formation, probably contribute to the pathogenesis of this disease 18 . Evidence from animal models of lupus suggests that abnormal germinal centre activity and T FH cells orchestrate the generation of lupus-related autoantibodies. Mice homozygous for Rc3h1 san (the san allele encoding the sanroque form of roquin-1,
Plasmablasts and SLE flare
Patients with SLE respond differentially to rituximab according to their levels of antibodies to double-stranded DNA (anti-dsDNA antibody) levels, the duration of B-cell depletion, and the type of B cell that dominates the early repopulation phase. Disease returns most quickly in patients whose B cells repopulate rapidly after rituximab therapy 6 . In this section, we discuss the evidence that an increased frequency of circulating plasmablasts in the B-cell pool following rituximab therapy is associated with SLE flares characterized by high levels of anti-dsDNA antibodies.
Among patients with SLE who relapse after rituximab therapy, those with high anti-dsDNA antibody levels have significantly fewer B-cells at the time of relapse than do patients without increased anti-dsDNA antibody levels 6 . Post-rituximab flare in patients with high anti-dsDNA antibody levels is characterized by an increased percentage of circulating plasmablasts within the
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Abstract | Suboptimal trial design and concurrent therapies are thought to account for the unexpected failure of two clinical trials of rituximab in patients with systemic lupus erythematosus (SLE). However, in this Opinion article we propose an alternative explanation: that rituximab can trigger a sequence of events that exacerbates disease in some patients with SLE. Post-rituximab SLE flares that are characterized by high levels of antibodies to double-stranded DNA are associated with elevated circulating BAFF (B-cell-activating factor, also known as TNF ligand superfamily member 13B or BLyS) levels, and a high proportion of plasmablasts within the B-cell pool. BAFF not only perpetuates autoreactive B cells (including plasmablasts), particularly when B-cell numbers are low, but also stimulates T follicular helper (T FH ) cells. Moreover, plasmablasts and T FH cells promote each others' formation. Thus, repeated rituximab infusions can result in a feedback loop characterized by ever-rising BAFF levels, surges in autoantibody production and worsening of disease. We argue that B-cell depletion should be swiftly followed by BAFF inhibition in patients with SLE. Rituximab disturbs BAFF homeostasis BAFF levels rise post-rituximab The predominance of plasmablasts in the repopulated B cells after rituximab treatment (in the context of an overall B-cell lymphopenia) and the potential of these plasmablasts to drive T FH cell formation might encourage clinicians to consider the use of increasing doses of rituximab in be initially skewed towards an autoreactive repertoire 23 . Whether a transient elevation in serum BAFF that returned to baseline before a relapse in disease would have an enduring adverse impact on the B-cell repertoire remained uncertain. However, a subsequent study clearly showed that elevated BAFF levels can persist in patients with SLE, but only in those who relapse with high antidsDNA antibody levels after rituximab treatment 22 , and that these high BAFF levels are likely to provide an environment in which autoreactive B cells flourish. By contrast, patients who flare following B-cell depletion but do not have high antidsDNA antibody levels do not have elevated serum levels of BAFF 22 . Studies in transgenic mice suggest that survival of autoreactive B-cell clones requires higher levels of BAFF than does maintenance of the self-tolerant population 26 . Consequently, the presence of elevated levels of BAFF lowers the stringency of B-cell selection and thereby rescues autoreactive clones that would otherwise be deleted [27] [28] [29] . In addition, BAFF supports the survival of plasmablasts 30 , whereas BAFF inhibition reduces the differentiation of naive marginal zone B cells into plasmablasts 31 . Increased production of BAFF by dendritic cells promotes plasmablast formation in patients with SLE 32 . Rising levels of BAFF following rituximab therapy, coupled with reduced B-cell competition, could remove the brakes on autoreactive B cells (including plasmablasts) and thereby trigger an SLE flare (FIG. 2) .
BAFF was first linked to lupus-like autoimmunity following the finding that mice engineered to constitutively express BAFF develop a lupus-like syndrome associated with autoantibodies against nuclear antigens 33, 34 . Serum BAFF levels are elevated in lupus-prone NZB/W F 1 mice and treatment of these mice with a BAFF antagonist ameliorated the progression of disease and improved survival 35 .
Clinical studies demonstrate that BAFF is overexpressed, either intermittently or persistently, in many patients with SLE 36, 37 , and that levels of BAFF correlate with serological and clinical indices of disease activity in such patients 38, 39 . Myeloid cells, B cells, T cells and neutrophils are all thought to contribute to the excess of BAFF observed in SLE -which is induced by a variety of signals, including type I interferons [40] [41] [42] and Toll-like receptor 9 (TLR9) activation 43 . In addition, the B-cell lymphopenia associated with active SLE 8 could also trigger a compensatory release patients with SLE, as has been suggested in rheumatoid arthritis (RA) 21 . However, postrituximab SLE flares that are accompanied by elevated anti-dsDNA antibody levels and low B-cell numbers are closely associated with increased BAFF levels 22 . BAFF is an important physiological mediator of B-cell homeostasis, and has a role in regulating survival and self-tolerance during B-cell development 23 . Serum BAFF levels are elevated immediately after rituximab therapy in patients with SLE 24 , but initial reports indicated that BAFF levels reverted to pretreatment values by 6 months, and were not associated with clinical relapse 24 . Similar observations were made in rituximab-treated patients with RA, in whom BAFF levels normalized upon B-cell repopulation and did not correlate with disease relapse 25 . Although these early data did not suggest that elevated BAFF levels directly contributed to disease flare postrituximab, the repopulated B-cells could of BAFF. Belimumab, a BAFF-neutralizing monoclonal antibody, has shown modest efficacy in phase 3 clinical trials, in patients with joint and skin manifestations of SLE, validating BAFF as an important therapeutic target 44 . Another therapeutic reagent that targets BAFF, tabalumab, has also shown some promise in phase 3 clinical trials, although a number of key end points were not achieved 45, 46 . BAFF receptor signalling exacerbates SLE Some debate remains as to which of the interactions between BAFF and its three receptors holds the key to pathogenicity in SLE, and it is possible that they all contribute. Knockout studies in NZM 2328 lupus-prone mice have demonstrated that any single BAFF receptor is dispensable to the development of lupus 47 . In vitro, BAFF has a proliferative effect on human mesangial cells via a BAFF-BAFF-R (BAFF receptor, also known as TNF receptor superfamily member 13C) interaction on the cell membrane 48 . In BAFF transgenic mice, deletion of TACI (transmembrane activator and CAML (calcium modulating ligand) interactor, also known as TNF receptor superfamily member 13B) on B cells protects against BAFF-mediated autoimmunity 49 . The least well-studied BAFF receptor, BCMA (B-cell maturation protein, also known as TNF receptor superfamily member 17), has a role in maintaining the survival of plasma cells 50 , but its exact role in autoimmunity remains unclear 51, 52 . The generation of two different BCMA-deficient lupus-prone mouse models, B6.lpr Tnfrsf17 −/− and Nba2 Tnfrsf17 −/− mice, which were expected to display milder disease than their wild-type counterparts, in fact developed accelerated proliferation of B cells and plasma cells with increased autoantibody production and early lethality 53 . These observations suggest that in the context of autoimmunity, BCMA might in fact have an inhibitory role in B-cell activation 53 . However, in the NZM 2328 mouse model of lupus, BCMA deficiency resulted in similar morbidity to that observed in wild-type mice 47 . Interestingly, subsequent experiments in NZM 2328 mice with various pairs of BAFF receptor deletions resulted in different clinical courses of disease: mice with BAFF-R and TACI deletions, or BAFF-R and BCMA deletions, developed attenuated disease compared with mice bearing all three BAFF receptors 54 . BAFF is also involved in the regulation of T FH cells (FIG. 1) . BAFF directly stimulates T-cell proliferation and cytokine lead to uncontrolled T FH cell differentiation and accumulation, whereas (at least in mice) BCMA has a role in downregulating T FH cells. Local BAFF production by T FH cells has been identified as important in promoting the survival of high-affinity B cells in germinal centres 58 . If this same mechanism is present in an autoreactive setting, it could foster diseases such as SLE 59 . Thus, development of therapies that target BAFF receptors might be an alternative strategy to BAFF blockade in SLE, but careful analysis of the results in both mice and humans will be required if untoward effects are to be avoided.
BAFF, anti-dsDNA levels and rituximab These various lines of evidence suggest, therefore, that B-cell depletion further distorts BAFF homeostasis in patients with SLE, leading to a closer association between BAFF levels and disease exacerbation than is evident in patients with SLE who have not been treated with rituximab. This situation might arise because the loss of B cells following rituximab therapy largely removes the major 'users' of circulating BAFF, thereby production 55, 56 ; moreover, BAFF blockade in BCMA-deficient Nba2 mice (which develop autoimmune disease) resulted in markedly reduced numbers of T FH cells (as well as reductions in germinal centre B cells and plasma cells) in the spleens of these mice, suggesting an important role for BAFF in the maintenance of T FH cells in germinal centres 57 . However, administration of recombinant BAFF to BCMA-deficient mice (but not to wild-type mice) increased the numbers of total and germinal centre T FH cells, germinal centre B cells and plasma cells. These findings suggest that, in the absence of BCMA, excessive BAFF signalling via BAFF-R or TACI, or both, could be responsible for the proliferation of T FH cells, germinal centre B cells and splenic plasma cells.
Analysis of human T FH cells from patients with SLE found no evidence of BCMA expression; however, the percentage of T FH cells expressing BAFF-R was increased in T FH cells from patients with SLE compared with those from healthy donors 57 . We might speculate, therefore, that signals transduced through BAFF-R on human T FH cells could Relapse of systemic lupus erythematosus (SLE) before rituximab therapy is associated with a modest B-cell lymphopenia and an increased proportion of plasmablasts, compared with the situation in healthy individuals. Those patients who flare after rituximab treatment with elevated levels of antibodies to double-stranded DNA (anti-dsDNA antibodies) also have high levels of B-cell activating factor (BAFF, also known as TNF ligand superfamily member 13B or BLyS), often with very low B-cell numbers, among which autoreactive plasmablasts predominate. This phenomenon can be compounded by repeated rituximab infusions (see also FIG. 3) . By contrast, patients who remain in remission after B-cell depletion have moderate-to-low BAFF levels. Understanding the relationship between BAFF levels, B-cell subsets and SLE flare will be crucial for the appropriate selection of therapy in these patients. Anti . This mechanism, as well as the increased production of BAFF that drives B-cell repopulation, could contribute to the increased levels of BAFF observed in patients who relapse after rituximab therapy compared with both those in remission and those who experience flare before B-cell depletion 22 (FIG. 2) .
Changes in serum BAFF levels also correlate positively with changes in anti-dsDNA levels during relapse or remission after rituximab treatment: higher BAFF levels during flare were associated with higher anti-dsDNA levels 22 . Of greater concern is that consecutive flares in a proportion of previously rituximab-treated patients were characterized by incremental increases in levels of both anti-dsDNA antibodies and BAFF following each cycle of rituximab 22 (FIG. 3) . Indeed, approximately half of patients who relapse following rituximab therapy show increases in levels of both BAFF and anti-dsDNA antibodies 22 . These effects seem to be most marked in a subset of patients who undergo multiple cycles of B-cell depletion therapy 22 , highlighting a potential danger of re-treatment for some patients, especially as the most recent efficacy analysis revealed that one-third of the patients re-treated with rituximab received three or more cycles of this therapy 61 . We envisage the existence of a BAFF-driven feedback loop between plasmablasts and T FH cells that gains momentum with each successive rituximab infusion, leading to worsening of disease and accumulation of organ damage in a subset of patients with SLE.
B-cell depletion plus BAFF blockade
The principle of targeting more than one pathogenic mechanism to increase the efficacy of targeted therapies is gaining traction in several autoimmune disease settings. For example, multiple pathways could be targeted sequentially, to first induce remission and then to restore a state of immune tolerance to prevent reactivation of the disease process 63 . A thorough understanding of the mechanism of action of each biological therapy is important in deciding which combinations will work best to prevent resurgence of disease.
An obvious solution to prevent the rise in BAFF levels from precipitating an SLE flare following rituximab therapy (and thus to achieve sustained remission of disease) would be to combine rituximab with BAFF blockade, an approach that has been previously proposed 60 . In mice, a combination of B-cell depletion and BAFF inhibition removes B cells in the marginal zone and follicular compartments more effectively than either treatment alone 64 . A combination of B-cell depletion and BAFF blockade was superior to B-cell depletion alone with respect to reducing the numbers of plasmablasts and plasma cells, as well as reducing disease severity, in three different mouse models of lupus 65 . Belimumab has been used before rituximab treatment in patients with chronic lymphoid leukaemia. In this disease, the ability of natural killer (NK) cells to directly lyse malignant cells and to mediate antibodydependent cell-mediated cytotoxicity is compromised. NK cells produce BAFF, particularly when activated, and this This situation might apply only to patients with SLE whose post-rituximab flare is associated with high anti-dsDNA antibody levels. A comparison of the repeated use of B-cell-depletion therapy in SLE and in RA (in which this approach has proven efficacy) reveals differences with respect to BAFF levels after rituximab treatment. Although BAFF levels were elevated in patients with RA who were re-treated with rituximab (as also occurs in patients with SLE), each successive flare in the re-treated patients with RA did not lead to further increases in BAFF levels at onset of the next relapse 62 .
The researchers who conducted this study concluded that elevated serum BAFF levels were not related to the presence or absence of active RA 62 . These differences might contribute to why rituximab's effectiveness, including in patients receiving repeated courses of treatment, has been demonstrated in RA but not in SLE.
The balance of evidence suggests that the increasing BAFF levels that can arise following repeated cycles of rituximab have the potential to drive increasingly aggressive disease and consequent organ damage for some patients with SLE. Thus, although rituximab therapy might temporarily improve the disease, its repeated use could worsen long-term outcomes for some patients with SLE.
However, further work is needed to establish the effects of repeated rituximab infusions in patients with SLE, and to elucidate the mechanisms that control BAFF levels, B-cell repopulation and disease relapse. increase in BAFF enhances the metabolic activity of malignant cells and reduces their susceptibility to both direct NK-cell lysis and rituximab-induced antibody-dependent cell-mediated cytotoxicity 66 . Pretreatment with belimumab restored the sensitivity of malignant cells to rituximab-induced NK cell lysis 66 . We propose that post-rituximab flares characterized by increasing BAFF levels, low B-cell numbers and high anti-dsDNA antibody levels could, therefore, be effectively addressed by administration of a BAFF-blocking agent immediately following B-cell depletion. Although BAFF blockade and B-cell depletion were combined in preclinical studies in mice 64, 65 , it is unclear whether simultaneous administration is required or indeed the safest approach. In humans, the duration and magnitude of B-cell depletion that would be induced by simultaneous administration of combinations of belimumab and rituximab remain unknown. Although BAFF levels rise soon after rituximab therapy, it is very unusual for patients to experience an SLE flare before their B-cell levels have risen to >0.01 × 10 9 cells/l, or before 2 months after rituximab therapy 6 . We would accordingly recommend a flare-prevention strategy based on administration of belimumab 2 weeks after the final rituximab infusion (although we recognize that these timings might need to be revised). Such sequential administration might prevent the surge in BAFF levels from altering the B-cell autoreactive repertoire.
Whether this sequential treatment would increase the patient's risk of infection is also unknown, although no safety signal was seen in mouse studies using combinations of B-cell depletion and BAFF inhibition 64, 65 . It would be important to monitor B-cell repopulation and immunoglobulin levels in patients receiving belimumab after rituximab as surrogate indicators of safety with respect to infection. Moreover, the patient's responses to vaccination during and after this combination treatment are likely to be impaired, and patients should be advised to receive relevant vaccines some time before rituximab and belimumab are administered. Finally, as an alternative to belimumab, conventional immunosuppressive agents (such as mycophenolate mofetil) could be administered to suppress the surge in BAFF levels post-rituximab, although our observations suggest that incremental rises in BAFF levels can occur on a background of either mycophenolate mofetil or azathioprine therapy.
Ongoing clinical studies Two trials of rituximab followed by belimumab therapy are currently recruiting patients: the open-label CALIBRATE study (Rituximab and Belimumab for Lupus Nephritis) 67 and the SYNBIoSe study (Synergetic B-Cell Immodulation in SLE) 68 . A third randomized and double-blinded trial (unlike the other two, which are open-label) comparing belimumab with standard care in patients after rituximab therapy (BEAT-LUPUS) is planned in the UK. In addition to determining the efficacy of sequential B-cell-depletion and anti-BAFF therapy, these studies will provide a useful opportunity to dissect B-cell kinetics in rituximab-treated patients. Comparing the phenotypes, clonal relationships, and associated autoreactivity of B cells present at relapse and remission in rituximab-treated patients with SLE, with or without the addition of belimumab, is expected to yield insight into the mechanisms of relapse and whether tolerance can be restored.
Conclusions
Successive disease flares after rituximab therapy can be marked by rising levels of anti-dsDNA antibodies, a high frequency of plasmablasts and mounting levels of BAFF, in patients with SLE. Sequential treatments with rituximab seem to cause these incremental increases in BAFF levels in some patients -which, in the setting of low B-cell numbers, enable autoreactive B cells to thrive. BAFF can also promote the formation of plasmablasts and T FH cells and, therefore, accelerate germinal centre activity, leading to the expansion of autoantibody-secreting plasma cells. Compounding this effect, the early increase in plasmablast numbers after B-celldepletion therapy enhances the formation of T FH cells, creating a positive feedback loop that perpetuates antibody-driven inflammation in SLE. This sequence of events could explain why some patients with SLE fail to respond (or become refractory) to B-cell depletion therapy.
The evidence presented above provides the rationale for the addition of BAFF inhibition to prevent flares in rituximab-treated patients with SLE. Encouraging results have been obtained using this approach in animal models, and randomized controlled trials in humans are underway or about to start. If successful, this new treatment paradigm might prove to be a major leap forward in controlling SLE and inducing sustained remission in these patients.
